The Increasingly Human and Profitable Monoclonal Antibody Market

Abstract

The monoclonal antibody (mAb) market has changed rapidly in the past 5 years: it has doubled in size, becoming dominated by fully human molecules, launched bispecific molecules, and faced competition from biosimilars. We summarize the market in terms of therapeutic applications, type and structure of mAbs, dominant companies, manufacturing locations, and emerging markets.

Keywords: biosimilars; market analysis; monoclonal antibody.